Related Experiment Video
Updated: Jul 5, 2026

Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70
Published on: August 9, 2019
Rosiglitazone-induced anasarca without heart failure: capillary leakage?
Selcuk Dagdelen1, Mevlut Kurt, Kadriye Aydin
1Hacettepe University School of Medicine, Department of Endocrinology, Ankara Turkey. dagdelen@hacettepe.edu.tr
Severe edema from rosiglitazone and insulin in a type 2 diabetes patient occurred without heart dysfunction. Thiazolidinedione-induced pulmonary edema may not stem solely from congestive heart failure.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Thiazolidinediones, like rosiglitazone, are used to manage type 2 diabetes mellitus.
- Fluid retention is a known side effect, typically linked to cardiac decompensation.
Observation:
- A 68-year-old female with type 2 diabetes experienced life-threatening anasarca-type acute pulmonary edema.
- This severe edema was induced by rosiglitazone combined with insulin therapy.
Findings:
- The patient exhibited no evidence of left ventricular systolic or diastolic dysfunction.
- This case suggests severe thiazolidinedione-induced edema can occur independently of acute congestive heart failure.
Implications:
- Thiazolidinedione-induced pulmonary edema may arise from mechanisms other than cardiac failure, potentially involving increased vascular permeability.
- Cardiac monitoring alone may be insufficient for managing thiazolidinedione-associated pulmonary edema; reconsidering monitoring protocols is advised.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Ascites
Oral Hypoglycemic Agents: Biguanides and Glitazones
Heart Failure III: Clinical Manifestations
Diabetic Retinopathy
Pulmonary Edema II: Pathophysiology